Spontaneous reports of suspected adverse drug reactions
Retrospective Post-Marketing Safety Surveillance Study of Tofacitinib in Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA)
Canada
EU PAS number:
EUPAS46286
First published:
23/04/2024
Study
Finalised
Post-authorization Safety Study: Ponesimod Pregnancy Outcomes Program Utilizing Enhanced Pharmacovigilance Monitoring (POEM)
Austria
Belgium
Bulgaria
Canada
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS50031
First published:
12/12/2024
Study
Ongoing
International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study (INAS-NEES)
Czechia
Germany
Hungary
Italy
Poland
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS49984
First published:
20/06/2025
Study
Ongoing
Evaluation of pregnancy and infant outcomes in Mayzent patients using PRegnancy outcomes Intensive Monitoring (PRIM) data – The Mayzent-PRIM study
Switzerland
EU PAS number:
EUPAS45875
First published:
23/04/2024
Study
Ongoing
Evaluation of the absorption of colourless carotenoids and related compounds from food sources
Spain
EU PAS number:
EUPAS17479
First published:
13/06/2024
Study
Ongoing
Monitoring of the Lenalidomide Pregnancy Prevention Programme (PPP) Implementation and Effectiveness in Europe (Lena-PIE Europe)
Germany
EU PAS number:
EUPAS49520
First published:
02/07/2024
Study
Ongoing
Safety of psychotropic medication in pregnancy: A pharmacovigilance study of international safety data in the World Health Organization global individual case safety report (ICSR) database ‘VigiBase’.
Greece
EU PAS number:
EUPAS49262
First published:
23/04/2024
Study
Planned
Evaluation of adverse event clusters following immunization with mRNA COVID-19 vaccines: a real-world analysis using EudraVigilance data
Portugal
EU PAS number:
EUPAS43083
First published:
05/06/2025
Study
Ongoing
A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS) (ESPRIT)
Austria
Canada
Denmark
France
Germany
Greece
Ireland
Netherlands
Puerto Rico
Spain
Sweden
United Kingdom
United States
EU PAS number:
EUPAS30560
First published:
11/06/2024
Study
Finalised
Retrospective analysis of imaging and clinical features from patients treated with brolucizumab in post-marketing setting with reports of intraocular inflammation and/or retinal vascular occlusion
Switzerland
EU PAS number:
EUPAS41014
First published:
23/04/2024
Study
Finalised